For example, a two-arm open-labelled phase I trial evaluating the use of HPV-E6-specific TCR-T cells, with or without the anti-PD1 auto-secreted element, in the treatment of HPV+ve HNSCCs is currently underway in HPV-positive HNSCC patients (NCT03578406). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.